We are live on ! Find out more
ED

Exane Derivatives Portfolio holdings

AUM $174M
1-Year Est. Return 7.84%
This Fund
S&P 500
This Quarter Est. Return
+7.67%
1 Year Est. Return
-7.84%
3 Year Est. Return
+42.72%
5 Year Est. Return
+56.28%
10 Year Est. Return
AUM
$441M
AUM Growth
+$91.2M
Cap. Flow
+$74.5M
Cap. Flow %
16.9%
Top 10 Hldgs %
24.04%
Holding
1,099
New
222
Increased
266
Reduced
262
Closed
55

Top Buys

Rank Stock Value
1
UBS icon
UBS Group
UBS
+$15.4M
2
STLA icon
Stellantis
STLA
+$9.9M
3
ALC icon
Alcon
ALC
+$7.77M
4
AMZN icon
Amazon
AMZN
+$6.64M
5
RACE icon
Ferrari
RACE
+$5.26M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 15.26%
2 Technology 13.6%
3 Financials 12.86%
4 Healthcare 10.91%
5 Industrials 10.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PCH
476
DELISTED
PotlatchDeltic
PCH
$152K 0.03%
2,850
+2,839
+25,809% +$164K
MGP
477
DELISTED
MGM Growth Properties LLC Class A common shares representing limited liability company interests
MGP
$151K 0.03%
4,145
+239
+6% +$8.51K
LITE icon
478
Lumentum
LITE
$55.9B
$151K 0.03%
+1,837
New +$154K
ATRS
479
DELISTED
Antares Pharma, Inc.
ATRS
$150K 0.03%
+34,246
New +$140K
BDX icon
480
Becton Dickinson
BDX
$43.9B
$150K 0.03%
+618
New +$148K
GHG
481
GreenTree Hospitality
GHG
$113M
$149K 0.03%
13,752
+1,752
+15% +$23.3K
RUN icon
482
Sunrun
RUN
$2.35B
$149K 0.03%
2,795
-9,655
-78% -$466K
EWG icon
483
iShares MSCI Germany ETF
EWG
$1.55B
$148K 0.03%
4,237
VDE icon
484
Vanguard Energy ETF
VDE
$9.91B
$147K 0.03%
2,000
ANIP icon
485
ANI Pharmaceuticals
ANIP
$1.78B
$147K 0.03%
4,364
+4,355
+48,389% +$148K
CBAY
486
DELISTED
Cymabay Therapeutics
CBAY
$146K 0.03%
+34,214
New +$152K
BRX icon
487
Brixmor Property Group
BRX
$9.97B
$146K 0.03%
+6,423
New +$143K
CME icon
488
CME Group
CME
$92.2B
$146K 0.03%
693
+9
+1% +$1.9K
COO icon
489
Cooper Companies
COO
$13.8B
$144K 0.03%
1,412
-580
-29% -$56.8K
UE icon
490
Urban Edge Properties
UE
$2.96B
$144K 0.03%
7,683
+7,621
+12,292% +$144K
SYK icon
491
Stryker
SYK
$129B
$144K 0.03%
549
-219
-29% -$56K
MDGL icon
492
Madrigal Pharmaceuticals
MDGL
$12.8B
$143K 0.03%
+1,418
New +$168K
ZNGA
493
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
$143K 0.03%
13,451
-161
-1% -$1.7K
TBBK icon
494
The Bancorp
TBBK
$2.82B
$143K 0.03%
6,311
+2,845
+82% +$66.8K
VKTX icon
495
Viking Therapeutics
VKTX
$4.13B
$141K 0.03%
23,973
-21,109
-47% -$125K
EWW icon
496
iShares MSCI Mexico ETF
EWW
$1.91B
$141K 0.03%
3,004
+2,936
+4,318% +$139K
EW icon
497
Edwards Lifesciences
EW
$47.9B
$139K 0.03%
1,304
-495
-28% -$46.7K
BDEC icon
498
Innovator US Equity Buffer ETF December
BDEC
$216M
$138K 0.03%
4,151
OGN icon
499
Organon & Co
OGN
$3.55B
$138K 0.03%
+4,751
New +$156K
MIRM icon
500
Mirum Pharmaceuticals
MIRM
$6.97B
$138K 0.03%
+8,626
New +$155K

Similar funds

Exane Derivatives's Q2 2021 Portfolio in Review

As of Q2 2021, Exane Derivatives held 1,099 positions worth $441M, up 26% from $350M the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Exane Derivatives deployed $74.5M of net new capital in Q2 2021, opening 222 new positions and adding to 266 existing holdings. Its largest new stake was Alcon: 109,041 shares worth $7.62M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 15% of assets, up from 11% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was iShares MSCI Taiwan ETF, an estimated $8.02M trimmed.

  • Exane Derivatives's largest Q2 2021 buy was Alcon: 109,041 shares worth $7.62M.
  • Exane Derivatives added most to UBS Group in Q2 2021, an estimated $15.4M increase.
  • Exane Derivatives's biggest Q2 2021 reduction was iShares MSCI Taiwan ETF, cutting an estimated $8.02M.
  • Exane Derivatives fully exited Deutsche Bank in Q2 2021, selling an estimated $4.27M.
  • Exane Derivatives's ten largest holdings make up 24% of its $441M portfolio in Q2 2021.
  • Exane Derivatives opened 222 new positions and closed 55 in Q2 2021.
  • Exane Derivatives's portfolio value rose 26% quarter-over-quarter to $441M.

Based on Exane Derivatives's 13F filing for Q2 2021, filed 28 Jul 2021.